Alnylam Pharmaceuticals
ALNY
#738
Rank
$24.02 B
Marketcap
$192.96
Share price
0.34%
Change (1 day)
46.59%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/E ratio for Alnylam Pharmaceuticals (ALNY)

P/E ratio as of June 2023 (TTM): -22.2

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -22.2048. At the end of 2021 the company had a P/E ratio of -23.6.

P/E ratio history for Alnylam Pharmaceuticals from 2004 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2021-23.635.01%
2020-17.423.3%
2019-14.146.71%
2018-9.64-58.93%
2017-23.5200.45%
2016-7.82-71.36%
2015-27.344.59%
2014-18.9-58.03%
2013-45.0412.48%
2012-8.77

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
30.4-236.84%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
18.1-181.50%๐Ÿ‡ซ๐Ÿ‡ท France
19.2-186.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-10.2-54.22%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.7316-96.71%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.00-81.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-3.41-84.64%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
-190 756.14%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.